Business Context and Reporting Period
Company: Keros Therapeutics, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: January 30, 2025
Reporting Period: Single event date (January 30, 2025)
This filing serves as a Regulation FD disclosure to announce an upcoming investor presentation. It does not contain periodic financial results.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is an event notification and does not include financial statements or performance metrics.
Material Changes
No material financial changes versus a prior comparable period are reported in this filing. The document solely announces a scheduled corporate event.
Guidance, Outlook, and Management Commentary
- Upcoming Event: Jasbir Seehra, Chair and Chief Executive Officer, will participate in a fireside chat at the Guggenheim SMID Cap Biotech Conference.
- Event Date: Thursday, February 6, 2025.
- Event Time: 10:00 a.m. Eastern time.
- Legal Status: The information in this report and the accompanying press release (Exhibit 99.1) is furnished and not deemed "filed" for purposes of Section 18 of the Exchange Act. It is not incorporated by reference into other filings unless expressly stated.
Investor Verification Checklist
- Verify the date and time of the Guggenheim SMID Cap Biotech Conference presentation (February 6, 2025, 10:00 a.m. ET).
- Review the full text of the press release attached as Exhibit 99.1 for any additional details on the presentation agenda.
- Confirm that no financial data or forward-looking guidance was included in this specific 8-K filing.